首页> 外文期刊>老年心脏病学杂志(英文版) >Safety and efficacy of dalteparin in percutaneous coronary intervention in Chinese patients with non-ST-elevation acute coronary artery syndromes: comparison with unfractionated heparin
【24h】

Safety and efficacy of dalteparin in percutaneous coronary intervention in Chinese patients with non-ST-elevation acute coronary artery syndromes: comparison with unfractionated heparin

机译:达肝素在中国非ST段抬高型急性冠状动脉综合征患者中经皮冠状动脉介入治疗的安全性和有效性:与普通肝素比较

获取原文
获取原文并翻译 | 示例
       

摘要

Objective To prospectively evaluate the safety and therapeutic efficacy ofdalteparin in patients with high risk non-ST-elevation acute coronary syndromes (ACS) during percutaneous coronary intervention (PCI). Methods Atotal of 175 patients with high risk non-ST-elevation ACS were randomly assigned to 2 groups [dalteparin group and unfractionated heparin (UFH) group]. The patients in dalteparin group were given dalteparin at a dose of 5,000U subcutaneously soon after diagnosis and then an additional 60U/ kg intravenous bolus ofdalteparin before emergent PCI. Vascular access sheaths were removed immediately after PCI or coronary artery angiography; the patients in UFH group were given UFH intravenously at a dose of 25mgjust before PCI and an additional 65mg bolus was administered if angiographic findings showed that the patients were suitable for percutaneous transluminai coronary angioplasty (PTCA). Sheaths were removed at 4-6 hours after PCI; Results Eighty-three patients in dalteparin group underwent PCI while 82 patients in UFH group underwent PCI; anti-Xa activities of 52 patients in dalteparin group were measured. The average anti-Xa activity was (0.83±0.26) U/ml at 15 minutes after intravenous injection of dalteparin and anti-Xa>0.5U/ml was obtained in 96.1% of the patients; hematomas at puncture sites were significantly fewer in dalteparin group as compared with UFH group (2.3% vs 9. 2%, P < 0.05); none of the patients in 2 groups suffered major bleeding events. No death, acute arterial reocclusion or emergent revascularization events occurred at 30 days after PCI. Conclusions Our study demonstrated that early subcutaneous injection of dalteparin at a dose 5,000U after diagnosis and an additional 60U/kg intravenous bolus ofdalteparin before PCI is safe and efficacious for patients with high risk non-ST-elevation ACS undergoing emergent PCI
机译:目的前瞻性评估达肝素在经皮冠状动脉介入治疗(PCI)期间高危非ST段抬高急性冠脉综合征(ACS)患者中的安全性和疗效。方法将175例高危非ST段抬高型ACS患者随机分为2组(达肝素组和普通肝素(UFH)组)。达特肝素组的患者在诊断后不久皮下给予5,000U达特肝素,然后在出现PCI前再静脉给予60U / kg达特肝素静脉推注。 PCI或冠状动脉造影后应立即移除血管通路鞘; UFH组的患者在PCI之前就以25mg的剂量静脉内给予UFH,如果血管造影结果显示这些患者适合于经皮腔内冠状动脉成形术(PTCA),则应另外给予65mg推注。 PCI后4-6小时将鞘去除;结果达肝素组83例行PCI,UFH组82例行PCI。测定达肝素组52例患者的抗Xa活性。静脉注射达肝素15分钟后的平均抗Xa活性为(0.83±0.26)U / ml,96.1%的患者获得抗Xa> 0.5U / ml。与UFH组相比,达肝素组的穿刺部位血肿明显减少(2.3%比9. 2%,P <0.05)。两组患者均未发生大出血事件。 PCI后30天未发生死亡,急性动脉闭塞或紧急血运重建事件。结论我们的研究表明,诊断后早期皮下注射达肝素剂量为5,000U,在PCI之前额外静脉注射达肝素60U / kg对于高危非ST段抬高ACS急诊PCI的患者是安全有效的。

著录项

  • 来源
    《老年心脏病学杂志(英文版)》 |2009年第2期|95-98|共4页
  • 作者

    Xing Ke; Haichu Yu; Qixin Wang;

  • 作者单位

    Department of Emergency, Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China;

    Department of Emergency, Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China;

    Department of Emergency, Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China;

  • 收录信息 中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 内科学;
  • 关键词

  • 入库时间 2022-08-19 03:38:02
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号